Manufacturer with High Quality and Competitive Price
Commercial Supply Dapoxetine Hydrochloride and Related Intermediates:
3-Chloropropiophenone CAS: 936-59-4
(S)-3-Amino-3-Phenylpropan-1-ol CAS: 82769-76-4
(S)-3-Amino-3-Phenylpropanoic Acid CAS: 40856-44-8
(R)-Diphenylprolinol CAS: 22348-32-9
(S)-Diphenylprolinol CAS: 112068-01-6
(S)-(-)-3-Chloro-1-Phenyl-1-Propanol CAS: 100306-34-1
(R)-(+)-3-Chloro-1-Phenyl-1-Propanol CAS: 100306-33-0
3-Chloro-1-Phenyl-1-Propanol CAS: 18776-12-0
Dapoxetine CAS: 119356-77-3
Dapoxetine Hydrochloride CAS: 129938-20-1
| Chemical Name |
(S)-(-)-3-Chloro-1-Phenyl-1-Propanol |
| Synonyms |
(S)-(-)-α-(2-Chloroethyl)benzyl Alcohol |
| CAS Number |
100306-34-1 |
| CAT Number |
RF-CC116 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C9H11ClO |
| Molecular Weight |
170.64 |
| Density |
1.149 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Almost White Powder |
| Purity |
≥98.0% |
| Melting Point |
54.0℃~58.0℃ |
| Moisture (K.F) |
≤0. 50% |
| Test Standard |
Enterprise Standard |
| Usage |
Dapoxetine Hydrochloride (CAS: 129938-20-1) Intermediate |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Manufacturer with High Quality and Competitive Price
Commercial Supply Dapoxetine Hydrochloride and Related Intermediates:
3-Chloropropiophenone CAS: 936-59-4
(S)-3-Amino-3-Phenylpropan-1-ol CAS: 82769-76-4
(S)-3-Amino-3-Phenylpropanoic Acid CAS: 40856-44-8
(R)-Diphenylprolinol CAS: 22348-32-9
(S)-Diphenylprolinol CAS: 112068-01-6
(S)-(-)-3-Chloro-1-Phenyl-1-Propanol CAS: 100306-34-1
(R)-(+)-3-Chloro-1-Phenyl-1-Propanol CAS: 100306-33-0
3-Chloro-1-Phenyl-1-Propanol CAS: 18776-12-0
Dapoxetine CAS: 119356-77-3
Dapoxetine Hydrochloride CAS: 129938-20-1
Dapoxetine Hydrochloride (CAS: 129938-20-1) is a short-acting novel selective serotonin reuptake inhibitor marketed for the treatment of premature ejaculation in men. Premature ejaculation (PE) is the most common male sexual disorder, estimated to affect up to 30% of men.